Artwork

Content provided by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

STAMPEDE (part 3): Impact and legacy with Max Parmar & Nick James

23:23
 
Share
 

Manage episode 375116538 series 1631392
Content provided by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design and look forward to STAMPEDE2, sharing their hopes for the future of prostate cancer research. - Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly/3OQWhV8 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g
  continue reading

24 episodes

Artwork
iconShare
 
Manage episode 375116538 series 1631392
Content provided by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MRC CTU at UCL - Trial Talk podcast and MRC Clinical Trials Unit at UCL or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times. This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023. In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design and look forward to STAMPEDE2, sharing their hopes for the future of prostate cancer research. - Further information is available on the STAMPEDE study page at www.mrcctu.ucl.ac.uk For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk For more information and to access the transcript: bit.ly/3OQWhV8 As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g
  continue reading

24 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide